Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Rybelsus may trigger fatigue through slowed gastric emptying leading to reduced nutrient intake, GI side effects causing dehydration or electrolyte imbalance, mild hypoglycemia risk and a temporary shift toward fat burning that can lower energy. Individual factors like dosing pace, nutrition, hydration and other medications also play a role.
Whether you should switch medications hinges on balancing effectiveness with tolerability and exploring alternatives such as injectable GLP1s or other drug classes; see below for detailed guidance on management strategies and next steps with your healthcare provider.
Rybelsus (semaglutide) is a once-daily, oral GLP-1 receptor agonist used in type 2 diabetes management. It's proven to help control blood sugar and support modest weight loss. Yet some patients report persistent tiredness or fatigue after starting Rybelsus. Understanding why does Rybelsus cause fatigue, how to manage it, and whether you should consider switching medications can help you make informed decisions about your diabetes care.
Rybelsus mimics the hormone GLP-1 (glucagon-like peptide-1), which:
Clinical trials and FDA data confirm Rybelsus's benefits in glycemic control and weight management. However, its impact on the gastrointestinal tract and metabolism can lead to side effects—fatigue being one of the more puzzling complaints.
Fatigue linked to Rybelsus stems from several interconnected mechanisms:
Slowed Gastric Emptying
Gastrointestinal Side Effects
Hypoglycemia (Low Blood Sugar)
Altered Energy Metabolism
Individual Variation
Fatigue is common during the first few weeks of Rybelsus therapy, but it usually subsides as your body adjusts. You may be at higher risk if you:
When to seek medical attention:
You don't have to resign yourself to low energy. Try these strategies:
Titrate Slowly
Optimize Nutrition
Stay Hydrated
Monitor Blood Sugar Closely
Adjust Activity Levels
Assess Other Medications & Conditions
Deciding to switch from Rybelsus isn't one-size-fits-all. Consider:
Effectiveness vs. Tolerability
Alternative GLP-1 Options
Different Drug Classes
Cost, Coverage, & Convenience
Before making any changes, weigh the pros and cons in collaboration with your healthcare provider.
If fatigue is interfering with your quality of life or you experience alarming symptoms, don't wait. To get personalized insights about your symptoms and understand whether they might be medication-related or signal something else, try Ubie's free Medically approved AI Symptom Checker Chat Bot for an initial assessment before your doctor visit.
Always speak to a doctor about any serious or life-threatening concerns. They can:
Fatigue on Rybelsus is usually manageable with proper dosing, nutrition, and hydration. However, persistent or severe tiredness warrants professional evaluation. Speak to your healthcare provider before making any medication changes. Your energy and well-being matter—don't hesitate to seek help.
(References)
* Rodbard HW, Rosenstock J, Sugimoto D, et al. Safety and tolerability of oral semaglutide in type 2 diabetes: a pooled analysis of the PIONEER clinical trial program. Diabetes Obes Metab. 2020 Mar;22 Suppl 1:55-64. doi: 10.1111/dom.13955. Epub 2020 Mar 22. PMID: 32249539.
* Cai J, Li B, Han X, Li M, Cao B, Liu H. Efficacy and Safety of Oral Semaglutide in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes Ther. 2020 Aug;11(8):1723-1736. doi: 10.1007/s13300-020-00868-y. Epub 2020 Jul 15. PMID: 32668984. PMCID: PMC7389808.
* Kalra S, Das AK, Sanyal D, et al. Oral semaglutide for type 2 diabetes: a comprehensive review of clinical efficacy, safety, and patient experience. Diabetes Ther. 2021 Apr;12(4):947-972. doi: 10.1007/s13300-021-01007-z. Epub 2021 Feb 5. PMID: 33512592. PMCID: PMC7965039.
* Davies MJ, Rossing P, Kadowaki T, et al. Patient-Reported Outcomes and Treatment Discontinuation in Patients with Type 2 Diabetes Treated with Oral Semaglutide: A Post Hoc Analysis of the PIONEER 1-5, 7, and 8 Trials. Diabetes Ther. 2021 Oct;12(10):2731-2746. doi: 10.1007/s13300-021-01103-y. Epub 2021 Aug 14. PMID: 34390312. PMCID: PMC8492021.
* Nauck MA. Adverse effects of glucagon-like peptide-1 receptor agonists. Adv Exp Med Biol. 2018;1067:235-252. doi: 10.1007/978-3-319-77877-2_16. PMID: 29849500.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.